Lung | Tumor

Lung Cancer

Lung Cancer – The two main forms are small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Non-small cell is by far the most common making up 80-85 percent of all cases. The three most common subcategories within Non-small cell are Adenocarcinoma, Squamous Cell Carcinoma, and Large Cell Carcinoma. Carcinoma is just a fancy word for what type of cells cancer started in.

Symptoms – symptoms can be very difficult to detect early on because the manifestations are often the same as those seen from common illnesses such as a cold or the flu. Common signs and symptoms range from coughing, wheezing, fatigue, pain in the chest, (earlier symptoms) to hoarseness, fluid in the lining of the heart, or fluid in the lining of the lungs (usually later symptoms). There can also be localized symptoms in any area cancer has spread to for example stomach pain on the right side due to cancer had reached the liver. Lung cancer can easily spread to the lymphatic system (your lymph nodes) and spread from there directly to other organs in your body. If you suspect your symptoms are lung cancer please talk to your healthcare provider right away.

Staging of Small Cell VS Non-Small Cell Cancer – Small Cell Lung Cancer is faster-growing cancer and is usually staged by where/if cancer has spread in the body using the terms limited or extensive while Non-Small Cell is staged using a Roman scale I-IV with I being the least severe and Stage IV Lung Cancer being the most severe.

Stage 4 Lung Cancer – when cancer originated in the lungs and begins to spread to other organs it is considered stage 4 means cancer has metastasized and on the move. This is aggressive cancer that traditionally requires aggressive treatment.

Ribbon – The awareness ribbon for lung cancer is white

Cancer Horizons strives to gather information about lung cancer and present it in plain and understandable terms for everyone. If you have an article or other content to refer to us or wish to contribute content please let us know.

Molecular Genotype Testing May Improve Lung Cancer Outcomes

December 29th 2023, 4:00pm

Article

Obtaining molecular genotyping results before first-line treatment resulted in better outcomes for patients with non-small cell lung cancer, an expert explained.

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

December 21st 2023, 2:00pm

Article

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing.

Robotic Lung Cancer Surgery Improves Quality of Life ‘100 Fold’

December 19th 2023, 10:00pm

Article

An expert discusses how the use of robotic surgery improves the lives of patients with cancer, and looks forward to advancements that may come in 2024 and beyond.

Next-Generation Sequencing Helps ‘Select the Best Treatment’ for Lung Cancer

December 15th 2023, 2:00pm

Article

Undergoing next-generation sequencing before receiving treatment can benefit patients with lung cancer and their doctors, as one expert told CURE®.

Differences Between Lung Cancer and Pleural Mesothelioma

November 16th 2023, 10:00pm

Article

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments.

What is a BRAF Mutation and Why is it Targeted in Lung Cancer Treatment?

October 19th 2023, 7:00pm

Article

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news.

Comparing Small Cell and Non-Small Cell Lung Cancer

August 11th 2023, 7:00pm

Article

There are two different types of lung cancer — small cell and non-small cell lung cancer — that behave differently and therefore require different treatments, an expert explained.

Exciting Lung Cancer Advances from 2023

August 1st 2023, 7:00pm

Article

In honor of World Lung Cancer Day, we took a look back at some of the exciting progress being made in the space.

Immunotherapy Plus Chemo Benefits Patients with NSCLC

July 27th 2023, 1:00pm

Article

Patients with a history of proton pump inhibitor use and who have NSCLC with a PD-L1 tumor proportion score of 50% or more benefit from immune checkpoint inhibitor plus chemotherapy as treatment.

Immunotherapy May Improve Lung Cancer Outcomes, Reduce Side Effects

July 26th 2023, 3:00pm

Article

Recent developments in the use of immunotherapy for lung cancer have provided more treatment options for patients while potentially reducing side effect profiles.